By conjugating the cetuximab antibody to the modified starch and using its ability to actively target overexpressed EGFR HNSCC tumor cells, we aim to achieve the targeting of our delivery system for precise therapeutic outcomes. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.